KalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at TD Cowen

Analysts at TD Cowen initiated coverage on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a note issued to investors on Tuesday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $30.00 price target on the specialty pharmaceutical company’s stock. TD Cowen’s target price points to a potential upside of 245.62% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Finally, Bank of America began coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, KalVista Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $25.00.

KalVista Pharmaceuticals Price Performance

NASDAQ KALV opened at $8.68 on Tuesday. KalVista Pharmaceuticals has a 1 year low of $7.97 and a 1 year high of $16.88. The company has a market capitalization of $428.95 million, a PE ratio of -2.38 and a beta of 0.86. The company has a fifty day moving average of $9.62 and a 200 day moving average of $11.39.

Insider Activity

In other news, CEO Benjamin L. Palleiko sold 14,400 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $133,344.00. Following the sale, the chief executive officer now owns 266,598 shares in the company, valued at $2,468,697.48. This trade represents a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Paul K. Audhya sold 8,077 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the transaction, the insider now owns 94,199 shares of the company’s stock, valued at approximately $872,282.74. This trade represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,291 shares of company stock worth $304,086 over the last three months. 10.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. HighVista Strategies LLC raised its stake in KalVista Pharmaceuticals by 4.5% in the 3rd quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock valued at $386,000 after purchasing an additional 1,432 shares during the last quarter. ClariVest Asset Management LLC grew its holdings in shares of KalVista Pharmaceuticals by 2.8% during the second quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company’s stock worth $673,000 after buying an additional 1,535 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of KalVista Pharmaceuticals by 8.0% in the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock valued at $262,000 after buying an additional 1,670 shares during the last quarter. Nicholas Investment Partners LP lifted its stake in shares of KalVista Pharmaceuticals by 0.9% in the second quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company’s stock worth $2,172,000 after buying an additional 1,714 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of KalVista Pharmaceuticals by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock worth $182,000 after buying an additional 3,314 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).